Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Vaccines

  Free Subscription


Articles published in J Infect Dis

Retrieve available abstracts of 233 articles:
HTML format



Single Articles


    November 2022
  1. MONTO AS, Lauring AS, Martin ET
    SARS-CoV-2 Vaccine Strain Selection: Guidance from Influenza.
    J Infect Dis. 2022 Nov 25:jiac454. doi: 10.1093.
    PubMed     Abstract available


  2. VANNIER E, Richer LM, Dinh DM, Brisson D, et al
    Deployment of a reservoir-targeted vaccine against Borreliella burgdorferi reduces the prevalence of Babesia microti coinfection in Ixodes scapularis ticks.
    J Infect Dis. 2022 Nov 23:jiac462. doi: 10.1093.
    PubMed     Abstract available


  3. WANG X, Zein J, Ji X, Lin DY, et al
    Impact of Vaccination, Prior Infection and Therapy on Omicron Infection and Mortality.
    J Infect Dis. 2022 Nov 23:jiac460. doi: 10.1093.
    PubMed     Abstract available


  4. DESILVA MB, Mitchell PK, Klein NP, Dixon BE, et al
    Protection of 2 and 3 mRNA Vaccine Doses Against Severe Outcomes Among Adults Hospitalized with COVID-19 - VISION Network, August 2021 - March 2022.
    J Infect Dis. 2022 Nov 23:jiac458. doi: 10.1093.
    PubMed     Abstract available


  5. TOMETTEN I, Landmann S, Kantauskaite M, Lamberti J, et al
    Factors associated with vaccine-induced T cell immune responses against SARS-CoV-2 in kidney transplant recipients.
    J Infect Dis. 2022 Nov 21:jiac449. doi: 10.1093.
    PubMed     Abstract available


  6. ILCHMANN H, Samy N, Reichhardt D, Schmidt D, et al
    Single and 2-dose vaccinations with modified vaccinia Ankara-Bavarian Nordic(R) induce durable B cell memory responses comparable to replicating smallpox vaccines.
    J Infect Dis. 2022 Nov 21:jiac455. doi: 10.1093.
    PubMed     Abstract available


  7. LIND ML, Copin R, McCarthy S, Coppi A, et al
    Use of whole genome sequencing to estimate the contribution of immune evasion and waning immunity on decreasing COVID-19 vaccine effectiveness.
    J Infect Dis. 2022 Nov 21:jiac453. doi: 10.1093.
    PubMed     Abstract available


  8. JONGKEES MJ, Geers D, Hensley KS, Huisman W, et al
    Immunogenicity of an additional mRNA-1273 SARS-CoV-2 vaccination in people with HIV with hyporesponse after primary vaccination.
    J Infect Dis. 2022 Nov 19:jiac451. doi: 10.1093.
    PubMed     Abstract available


  9. EIDEN J, Fierro C, Schwartz H, Adams M, et al
    Intranasal M2SR (M2-deficient Single Replication) H3N2 Influenza Vaccine Provides Enhanced Mucosal and Serum Antibodies In Adults.
    J Infect Dis. 2022 Nov 9. pii: 6807529. doi: 10.1093.
    PubMed     Abstract available


  10. STIEH DJ, Barouch DH, Comeaux C, Sarnecki M, et al
    Safety and Immunogenicity of Ad26-vectored HIV Vaccine with Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-uninfected Adults: A Phase 1/2a Study.
    J Infect Dis. 2022 Nov 9. pii: 6812747. doi: 10.1093.
    PubMed     Abstract available


  11. JAGER M, Dichtl S, Bellmann-Weiler R, Reindl M, et al
    Serum neutralization against SARS-CoV-2 variants is heterogenic and depends on vaccination regimen.
    J Infect Dis. 2022 Nov 1. pii: 6783141. doi: 10.1093.
    PubMed     Abstract available


  12. KUO TY, Lien CE, Lin YJ, Lin MY, et al
    Hamsters Protected from SARS-CoV-2 Delta Variant Challenge after Two Doses of Adjuvanted SARS-CoV-2 Recombinant Spike Protein (S-2P) and One Dose of Beta S-2P.
    J Infect Dis. 2022;226:1562-1567.
    PubMed     Abstract available


  13. MIDDLETON BF, Danchin M, Jones MA, Leach AJ, et al
    Immunogenicity of a Third Scheduled Dose of Rotarix in Australian Indigenous Infants: A Phase IV, Double-blind, Randomized, Placebo-Controlled Clinical Trial.
    J Infect Dis. 2022;226:1537-1544.
    PubMed     Abstract available


    October 2022
  14. DE SILVA A, White L
    Immunogenicity of a live dengue vaccine (TAK-003).
    J Infect Dis. 2022 Oct 26. pii: 6774399. doi: 10.1093.
    PubMed    


  15. ROE MK, Perez MA, Hsiao HM, Lapp SA, et al
    An RSV live-attenuated vaccine candidate lacking G protein mucin domains is attenuated, immunogenic, and effective in preventing RSV in BALB/c mice.
    J Infect Dis. 2022 Oct 25. pii: 6770706. doi: 10.1093.
    PubMed     Abstract available


  16. LEUNG J, Dooling K, Marin M, Anderson TC, et al
    The Impact of Universal Varicella Vaccination on Herpes Zoster Incidence in the United States: Comparison of Birth Cohorts Preceding and Following Varicella Vaccination Program Launch.
    J Infect Dis. 2022;226.
    PubMed     Abstract available


  17. MARIN M, Leung J, Anderson TC, Lopez AS, et al
    Monitoring Varicella Vaccine Impact on Varicella Incidence in the United States: Surveillance Challenges and Changing Epidemiology, 1995-2019.
    J Infect Dis. 2022;226.
    PubMed     Abstract available


  18. WILLIS ED, Marko AM, Rasmussen SA, McGee M, et al
    Merck/Centers for Disease Control and Prevention Varicella Vaccine Pregnancy Registry: 19-Year Summary of Data From Inception Through Closure, 1995-2013.
    J Infect Dis. 2022;226.
    PubMed     Abstract available


  19. ARVIN AM
    Insights From Studies of the Genetics, Pathogenesis, and Immunogenicity of the Varicella Vaccine.
    J Infect Dis. 2022;226.
    PubMed     Abstract available


  20. MARIN M, Lopez AS, Melgar M, Dooling K, et al
    Decline in Severe Varicella Disease During the United States Varicella Vaccination Program: Hospitalizations and Deaths, 1990-2019.
    J Infect Dis. 2022;226.
    PubMed     Abstract available


  21. LEUNG J, Lopez AS, Marin M
    Changing Epidemiology of Varicella Outbreaks in the United States During the Varicella Vaccination Program, 1995-2019.
    J Infect Dis. 2022;226.
    PubMed     Abstract available


  22. DOLLARD S, Chen MH, Lindstrom S, Marin M, et al
    Diagnostic and Immunologic Testing for Varicella in the Era of High-Impact Varicella Vaccination: An Evolving Problem.
    J Infect Dis. 2022;226.
    PubMed     Abstract available


  23. DREES M, Weber DJ
    Prevention and Control of Nosocomial Varicella During the United States Varicella Vaccination Program Era.
    J Infect Dis. 2022;226.
    PubMed     Abstract available


  24. ELAM-EVANS LD, Valier MR, Fredua B, Zell E, et al
    Celebrating 25 Years of Varicella Vaccination Coverage for Children and Adolescents in the United States: A Success Story.
    J Infect Dis. 2022;226.
    PubMed     Abstract available


  25. ZHOU F, Leung J, Marin M, Dooling KL, et al
    Health and Economic Impact of the United States Varicella Vaccination Program, 1996-2020.
    J Infect Dis. 2022;226.
    PubMed     Abstract available


  26. MORO PL, Leung J, Marquez P, Kim Y, et al
    Safety Surveillance of Varicella Vaccines in the Vaccine Adverse Event Reporting System, United States, 2006-2020.
    J Infect Dis. 2022;226.
    PubMed     Abstract available


  27. MARIN M, Seward JF, Gershon AA
    25 Years of Varicella Vaccination in the United States.
    J Infect Dis. 2022;226.
    PubMed    


  28. SHAPIRO ED, Marin M
    The Effectiveness of Varicella Vaccine: 25 Years of Postlicensure Experience in the United States.
    J Infect Dis. 2022;226.
    PubMed     Abstract available


  29. DOOLING K, Marin M, Gershon AA
    Clinical Manifestations of Varicella: Disease Is Largely Forgotten, but It's Not Gone.
    J Infect Dis. 2022;226.
    PubMed     Abstract available


  30. ANDERSON M, Stec M, Gosha A, Mohammad T, et al
    Longitudinal SARS-CoV-2 Vaccine Antibody Responses and Identification of Vaccine Breakthrough Infections Among Healthcare Workers Using Nucleocapsid IgG.
    J Infect Dis. 2022 Oct 20. pii: 6764413. doi: 10.1093.
    PubMed     Abstract available


  31. LAAKE I, Skodvin SN, Blix K, Caspersen IH, et al
    Effectiveness of mRNA booster vaccination against mild, moderate, and severe COVID-19 caused by the Omicron variant in a large, population-based, Norwegian cohort.
    J Infect Dis. 2022 Oct 19. pii: 6763324. doi: 10.1093.
    PubMed     Abstract available


  32. STUART A, Virta M, Williams K, Seppa I, et al
    Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector RSV Vaccine Encoding Prefusion F in Adults 18-50 Years and RSV Seropositive Children 12-24 Months.
    J Infect Dis. 2022 Oct 19. pii: 6763323. doi: 10.1093.
    PubMed     Abstract available


  33. AGALLOU M, Koutsoni OS, Michail M, Zisimopoulou P, et al
    Antibody and T cell subsets analysis unveils an immune profile heterogeneity mediating long-term responses in individuals vaccinated against SARS-CoV-2.
    J Infect Dis. 2022 Oct 19. pii: 6763327. doi: 10.1093.
    PubMed     Abstract available


  34. BADIZADEGAN K, Kalkowska DA, Thompson KM
    Polio by the Numbers-A Global Perspective.
    J Infect Dis. 2022;226:1309-1318.
    PubMed     Abstract available


  35. SHOVER CL, Rosen A, Mata J, Robie B, et al
    Engaging Same-Day Peer Ambassadors to Increase Coronavirus Disease 2019 Vaccination Among People Experiencing Unsheltered Homelessness in Los Angeles County: A Hybrid Feasibility-Evaluation Study.
    J Infect Dis. 2022;226.
    PubMed     Abstract available


  36. GIBSON C, Schumann C, Neuschel K, McBride JA, et al
    COVID-19 Vaccination Coverage Among People Experiencing Homelessness in a Highly Vaccinated Midwest County-Dane County, Wisconsin, 2021.
    J Infect Dis. 2022;226.
    PubMed     Abstract available


  37. RUDMANN KC, Brown NE, Rubis AB, Burns M, et al
    Invasive Meningococcal Disease Among People Experiencing Homelessness-United States, 2016-2019.
    J Infect Dis. 2022;226.
    PubMed     Abstract available


  38. BENET S, Blanch-Lombarte O, Ainsua-Enrich E, Pedreno-Lopez N, et al
    Limited humoral and specific T-cell responses after SARS-CoV-2 vaccination in PLWH with poor immune reconstitution.
    J Infect Dis. 2022 Oct 6. pii: 6749018. doi: 10.1093.
    PubMed     Abstract available


  39. CHAN CEZ, Wong SKK, Yazid NBM, Ng OT, et al
    Residual humoral immunity sustained over decades in a cohort of vaccinia-vaccinated individuals.
    J Infect Dis. 2022 Oct 6. pii: 6749013. doi: 10.1093.
    PubMed     Abstract available


  40. ASAMOAH-BOAHENG M, Goldfarb DM, Karim ME, O'Brien SF, et al
    The relationship between anti-spike SARS-CoV-2 antibody levels and risk of breakthrough COVID-19 among fully vaccinated adults.
    J Infect Dis. 2022 Oct 5. pii: 6748952. doi: 10.1093.
    PubMed     Abstract available


    September 2022
  41. FURUKAWA K, Kurahashi Y, Ishimaru H, Nishimura M, et al
    The number of COVID-19 vaccine doses and severe clinical outcomes in older patients infected with a SARS-CoV-2 Omicron variant.
    J Infect Dis. 2022 Sep 26. pii: 6717967. doi: 10.1093.
    PubMed    


  42. AMANO M, Otsu S, Ichikawa Y, Higashi-Kuwata N, et al
    Restoration of neutralization activity against Omicrons BA.2 and BA.5 in older adults and individuals with risk factors following the 4th-dose of SARS-CoV-2 BNT162b2 vaccine.
    J Infect Dis. 2022 Sep 22. pii: 6711120. doi: 10.1093.
    PubMed    


  43. LUNA-MUSCHI A, Noguera SV, Borges IC, De Paula AV, et al
    Characterization of SARS-CoV-2 Omicron variant shedding and predictors of viral culture positivity on vaccinated healthcare workers with mild COVID-19.
    J Infect Dis. 2022 Sep 22. pii: 6711076. doi: 10.1093.
    PubMed     Abstract available


  44. BRAZER N, Morris MK, Servellita V, Anglin K, et al
    Neutralizing immunity induced against the Omicron BA.1 and BA.2 variants in vaccine breakthrough infections.
    J Infect Dis. 2022 Sep 22. pii: 6711075. doi: 10.1093.
    PubMed     Abstract available


  45. KLUGMAN KP, Rodgers GL
    Pneumococcal carriage and sero-epidemiology studies to measure current and future pneumococcal conjugate vaccine effectiveness.
    J Infect Dis. 2022 Sep 21. pii: 6710232. doi: 10.1093.
    PubMed    


  46. ROSSLER A, Kimpel J, Fleischer V, Huber S, et al
    Regimen of COVID-19 vaccination influences extent and kinetics of antibody avidity.
    J Infect Dis. 2022 Sep 16. pii: 6701886. doi: 10.1093.
    PubMed     Abstract available


  47. COWLING BJ, Cheng SMS, Martin-Sanchez M, Au NYM, et al
    Slow waning of antibodies following a third dose of BNT162b2 in adults who had previously received two doses of inactivated vaccine.
    J Infect Dis. 2022 Sep 15. pii: 6701635. doi: 10.1093.
    PubMed     Abstract available


  48. KU JH, Levin MJ, Luo Y, Florea A, et al
    Risk of Severe Coronavirus Disease 2019 Disease in Individuals With Down Syndrome: A Matched Cohort Study From a Large, Integrated Health Care System.
    J Infect Dis. 2022;226:757-765.
    PubMed     Abstract available


  49. GOLDSTEIN N, Bockstal V, Bart S, Luhn K, et al
    Safety and Immunogenicity of Heterologous and Homologous 2-Dose Regimens of Adenovirus Serotype 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized, Controlled Phase 1 Study.
    J Infect Dis. 2022;226:595-607.
    PubMed     Abstract available


  50. YANG B, Wong IOL, Xiao J, Tsang TK, et al
    Effectiveness of CoronaVac and BNT162b2 vaccine against SARS-CoV-2 Omicron BA.2 infections in Hong Kong.
    J Infect Dis. 2022 Sep 2. pii: 6687716. doi: 10.1093.
    PubMed     Abstract available


    August 2022
  51. SHAW AG, Cooper LV, Gumede N, Bandyopadhyay AS, et al
    Time Taken to Detect and Respond to Polio Outbreaks in Africa and the Potential Impact of Direct Molecular Detection and Nanopore Sequencing.
    J Infect Dis. 2022;226:453-462.
    PubMed     Abstract available


  52. SADOFF J, De Paepe E, DeVincenzo J, Gymnopoulou E, et al
    Prevention of Respiratory Syncytial Virus Infection in Healthy Adults by a Single Immunization of Ad26.RSV.preF in a Human Challenge Study.
    J Infect Dis. 2022;226:396-406.
    PubMed     Abstract available


  53. BEALL B, Chochua S, Li Z, Tran T, et al
    Invasive Pneumococcal Disease Clusters Disproportionally Impact Persons Experiencing Homelessness, Injecting Drug Users, and the Western United States.
    J Infect Dis. 2022;226:332-341.
    PubMed     Abstract available


  54. TORNELL A, Grauers Wiktorin H, Ringlander J, Arabpour M, et al
    Rapid Cytokine Release Assays for Analysis of Severe Acute Respiratory Syndrome Coronavirus 2-Specific T Cells in Whole Blood.
    J Infect Dis. 2022;226:208-216.
    PubMed     Abstract available


  55. QUACH HQ, Chen J, Monroe JM, Ratishvili T, et al
    The influence of sex, BMI, and age on cellular and humoral immune responses against measles after a 3rd dose of MMR vaccine.
    J Infect Dis. 2022 Aug 22. pii: 6673362. doi: 10.1093.
    PubMed     Abstract available


  56. MIYAKAWA K, Kato H, Ohtake N, Stanleyraj Jeremiah S, et al
    Enhancement of humoral and cellular immunity against SARS-CoV-2 by a third dose of BNT162b2 vaccine in Japanese healthcare workers.
    J Infect Dis. 2022 Aug 18. pii: 6670905. doi: 10.1093.
    PubMed     Abstract available


  57. GOMEZ GB, Nelson CB, Rizzo C, Shepard DS, et al
    Inequalities in Health Impact of Alternative Reimbursement Pathways for Nirsevimab in the United States.
    J Infect Dis. 2022;226.
    PubMed     Abstract available


  58. HOA LNM, Sullivan SG, Mai LQ, Khvorov A, et al
    Influenza A(H1N1)pdm09 But Not A(H3N2) Virus Infection Induces Durable Seroprotection: Results From the Ha Nam Cohort.
    J Infect Dis. 2022;226:59-69.
    PubMed     Abstract available


  59. CRAVENS M, Alugupalli AS, Sandilya VK, McGeady SJ, et al
    The IgM response to pneumococcal polysaccharide vaccine is sufficient for conferring immunity.
    J Infect Dis. 2022 Aug 6. pii: 6657690. doi: 10.1093.
    PubMed     Abstract available


  60. GREBE E, Yu EA, Bravo MD, Welte A, et al
    COVID-19 vaccine effectiveness against SARS-CoV-2 infection in the United States prior to the Delta and Omicron-associated surges: a retrospective cohort study of repeat blood donors.
    J Infect Dis. 2022 Aug 3. pii: 6654836. doi: 10.1093.
    PubMed     Abstract available


    July 2022
  61. VIVALDI G, Jolliffe DA, Faustini S, Shields AM, et al
    Correlation between post-vaccination anti-Spike antibody titres and protection against breakthrough SARS-CoV-2 infection: a population-based longitudinal study.
    J Infect Dis. 2022 Jul 30. pii: 6652292. doi: 10.1093.
    PubMed     Abstract available


  62. LEROUX-ROELS I, Davis MG, Steenackers K, Essink B, et al
    Safety and immunogenicity of a respiratory syncytial virus prefusion F (RSVPreF3) candidate vaccine in older adults: phase I/II randomized clinical trial.
    J Infect Dis. 2022 Jul 29. pii: 6651941. doi: 10.1093.
    PubMed     Abstract available


  63. KNOLL MD, Bennett JC, Yang Y, Quesada MG, et al
    Challenges inferring pneumococcal conjugate vaccine impact from bacterial surveillance data.
    J Infect Dis. 2022 Jul 28. pii: 6650942. doi: 10.1093.
    PubMed    


  64. CHU WM, Lee YH, Cheng-Chung Wei J, Lee YH, et al
    Comment on Recombinant Adjuvanted Zoster Vaccine and Reduced Risk of Coronavirus Disease 2019 Diagnosis and Hospitalization in Older Adults.
    J Infect Dis. 2022 Jul 26. pii: 6649924. doi: 10.1093.
    PubMed    


  65. CRISTINA CASSETTI M, Pierson TC, Jean Patterson L, Bok K, et al
    Prototype Pathogen Approach for Vaccine and Monoclonal Antibody Development: A Critical Component of the NIAID Plan for Pandemic Preparedness.
    J Infect Dis. 2022 Jul 25. pii: 6649664. doi: 10.1093.
    PubMed     Abstract available


  66. MAHANT A, Guerguis S, Blevins TP, Cheshenko N, et al
    Herpes Simplex Virus Glycoprotein D Antibodies Fail to Elicit Antibody-Dependent Cell-Mediated Cytotoxicity: Implications for Future Vaccines.
    J Infect Dis. 2022 Jul 14. pii: 6644507. doi: 10.1093.
    PubMed     Abstract available


  67. BRADFUTE S, Mertz G
    Immune responses to herpes simplex virus infection: implications for vaccine development.
    J Infect Dis. 2022 Jul 8. pii: 6633820. doi: 10.1093.
    PubMed    


  68. WAGNER AL, Sanchez N, Kubale J, Kuan G, et al
    Single dose vaccination among infants and toddlers provides modest protection against influenza illness which wanes after 5 months.
    J Infect Dis. 2022 Jul 7. pii: 6633354. doi: 10.1093.
    PubMed     Abstract available


  69. COSSU MV, Mileto D, Giacomelli A, Oreni L, et al
    Does the co-morbidity burden contribute to suboptimal immunological responses to COVID-19 vaccination in people living with HIV?
    J Infect Dis. 2022 Jul 7. pii: 6633353. doi: 10.1093.
    PubMed    


  70. ASSAWAKOSRI S, Suntronwong N, Yorsaeng R, Kanokudom S, et al
    Breakthrough infection by SARS-CoV-2 Delta and Omicron variants elicited immune response comparable to mRNA booster vaccination.
    J Infect Dis. 2022 Jul 5. pii: 6631219. doi: 10.1093.
    PubMed    


  71. REN Z, Sun R, Cui G, Wang H, et al
    Effects of Inactivated Vaccination on Humoral Immune Responses in Patients Infected with Delta or Omicron Variants.
    J Infect Dis. 2022 Jul 5. pii: 6631218. doi: 10.1093.
    PubMed    


  72. NYOMBAYIRE J, Ingabire R, Magod B, Mazzei A, et al
    Monitoring of adverse events in recipients of the 2-dose Ebola vaccine regimen of Ad26.ZEBOV followed by MVA-BN-Filo in the UMURINZI Ebola Vaccination Campaign.
    J Infect Dis. 2022 Jul 1. pii: 6625827. doi: 10.1093.
    PubMed     Abstract available


    June 2022
  73. DEMASO CR, Karwal L, Zahralban-Steele M, Dominguez D, et al
    Specificity and Breadth of the Neutralizing Antibody Response to a Live Attenuated Tetravalent Dengue Vaccine.
    J Infect Dis. 2022 Jun 30. pii: 6623496. doi: 10.1093.
    PubMed     Abstract available


  74. VENCALEK O, Beran J, Furst T, Kratka Z, et al
    Protection by vaccines and previous infection against the Omicron variant of SARS-CoV-2.
    J Infect Dis. 2022 Jun 28. pii: 6619238. doi: 10.1093.
    PubMed    


  75. LLIBRE JM, Revollo B, Aguilar S, Calomarde-Gomez C, et al
    Protection against severe clinical outcomes with adenovirus or mRNA SARS-CoV-2 vaccines in patients hospitalized with Covid-19.
    J Infect Dis. 2022 Jun 28. pii: 6619237. doi: 10.1093.
    PubMed    


  76. MOY JN, Anderson M, Shen X, Fu J, et al
    Neutralizing Antibody Activity to SARS-CoV-2 Delta (B.1.617.2) and Omicron (B.1.1.529) After One and Two Doses of BNT162b2 Vaccine in Infection-Naive and Previously-Infected Individuals.
    J Infect Dis. 2022 Jun 27. pii: 6618640. doi: 10.1093.
    PubMed     Abstract available


  77. AMJADI MF, Adyniec RR, Gupta S, Bashar SJ, et al
    Anti-membrane antibodies persist at least one year and discriminate between past COVID-19 infection and vaccination.
    J Infect Dis. 2022 Jun 27. pii: 6618636. doi: 10.1093.
    PubMed     Abstract available


  78. MOODIE Z, Dintwe O, Sawant S, Grove D, et al
    Analysis of the HVTN 702 Phase 2b-3 HIV-1 vaccine trial in South Africa assessing RV144 antibody and T-cell correlates of HIV-1 acquisition risk.
    J Infect Dis. 2022 Jun 27. pii: 6618597. doi: 10.1093.
    PubMed     Abstract available


  79. STRENG BMM, Bont M, Delemarre EM, Binnendijk RS, et al
    Decreased antibody response after SARS-CoV-2 vaccination in patients with Down Syndrome.
    J Infect Dis. 2022 Jun 24. pii: 6617441. doi: 10.1093.
    PubMed     Abstract available


  80. CUNNINGHAM CK, Karron RA, Muresan P, Kelly MS, et al
    Evaluation of Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccines RSV/DeltaNS2/Delta1313/I1314L and RSV/276 in RSV Seronegative Children.
    J Infect Dis. 2022 Jun 23. pii: 6613410. doi: 10.1093.
    PubMed     Abstract available


  81. VARESE A, Mazzitelli B, Diaz FE, Kjolhede MV, et al
    Omicron breakthrough infection after heterologous prime-boost vaccination induces a vigorous antibody response.
    J Infect Dis. 2022 Jun 20. pii: 6611839. doi: 10.1093.
    PubMed     Abstract available


  82. GUIRAKHOO F, Wang S, Wang CY, Kuo HK, et al
    High neutralizing antibody levels against SARS-CoV-2 Omicron BA.1 and BA.2 after UB-612 vaccine booster.
    J Infect Dis. 2022 Jun 20. pii: 6611838. doi: 10.1093.
    PubMed     Abstract available


  83. LEMASTER C, Geanes ES, Fraley ER, Selvarangan R, et al
    Vaccination after SARS-CoV-2 infection increased antibody avidity against the Omicron variant compared to vaccination alone.
    J Infect Dis. 2022 Jun 18. pii: 6609994. doi: 10.1093.
    PubMed     Abstract available


  84. DONATO CM, Roczo-Farkas S, Kirkwood CD, Barnes GL, et al
    Rotavirus Disease and Genotype Diversity in Older Children and Adults in Australia.
    J Infect Dis. 2022;225:2116-2126.
    PubMed     Abstract available


  85. SIEDNER MJ, Alba C, Fitzmaurice KP, Gilbert RF, et al
    Cost-effectiveness of COVID-19 vaccination in low- and middle-income countries.
    J Infect Dis. 2022 Jun 13. pii: 6606162. doi: 10.1093.
    PubMed     Abstract available


  86. JACOBSON JM
    Immune Responses to SARS-CoV-2 Vaccination in People With HIV: A Tale of Two Pandemics.
    J Infect Dis. 2022 Jun 7. pii: 6603522. doi: 10.1093.
    PubMed    


  87. LAPOINTE HR, Mwimanzi F, Cheung PK, Sang Y, et al
    People with HIV receiving suppressive antiretroviral therapy show typical antibody durability after dual COVID-19 vaccination, and strong third dose responses.
    J Infect Dis. 2022 Jun 7. pii: 6603521. doi: 10.1093.
    PubMed     Abstract available


  88. STORCH GA
    Respiratory syncytial virus (RSV) around the globe: data to help guide wise use of vaccines and anti-virals.
    J Infect Dis. 2022 Jun 6. pii: 6603523. doi: 10.1093.
    PubMed    


    May 2022
  89. ROSTAD CA, Chen X, Sun HY, Hussaini L, et al
    Functional antibody responses to SARS-CoV-2 variants in children with COVID-19, MIS-C, and after two doses of BNT162b2 vaccination.
    J Infect Dis. 2022 May 26. pii: 6593309. doi: 10.1093.
    PubMed     Abstract available


  90. OSTER G, Bornheimer R, Ottino K
    Letter to the Editor in Response to Hall EW, Weng MK, Harris AM, et al. Assessing the Cost-Utility of Universal Hepatitis B Vaccination Among Adults.
    J Infect Dis. 2022 May 26. pii: 6593317. doi: 10.1093.
    PubMed    


  91. NALIN D
    Cholera control requires reducing mortality along with vaccination programs.
    J Infect Dis. 2022 May 18. pii: 6588066. doi: 10.1093.
    PubMed    


  92. AMANO M, Maeda K, Tsuchiya K, Shimada S, et al
    Third-dose BNT162b2 vaccination elicits markedly high-level SARS-CoV-2-neutralizing antibodies in vaccinees who poorly responded to second dose in Japan.
    J Infect Dis. 2022 May 17. pii: 6587098. doi: 10.1093.
    PubMed    


  93. AZIZ AB, Verma H, Jeyaseelan V, Md Y, et al
    One full or two fractional doses of inactivated poliovirus vaccine for catch-up vaccination in older infants: A randomized clinical trial in Bangladesh.
    J Infect Dis. 2022 May 16. pii: 6586252. doi: 10.1093.
    PubMed     Abstract available


  94. FAUSTHER-BOVENDO H, Qiu X, Babuadze GG, Azizi H, et al
    Transient Liver Damage and Hemolysis Are Associated With an Inhibition of Ebola Virus Glycoprotein-Specific Antibody Response and Lymphopenia.
    J Infect Dis. 2022;225:1852-1855.
    PubMed     Abstract available


  95. BABER J, Arya M, Moodley Y, Jaques A, et al
    A Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine With and Without Adjuvant in Healthy Older Adults.
    J Infect Dis. 2022 May 11. pii: 6583554. doi: 10.1093.
    PubMed     Abstract available


  96. MWIMANZI F, Lapointe HR, Cheung PK, Sang Y, et al
    Older adults mount less durable humoral responses to two doses of COVID-19 mRNA vaccine, but strong initial responses to a third dose.
    J Infect Dis. 2022 May 11. pii: 6583561. doi: 10.1093.
    PubMed     Abstract available


  97. EL SAHLY HM, Baden LR, Essink B, Montefiori D, et al
    Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 COVE Trial.
    J Infect Dis. 2022 May 10. pii: 6583011. doi: 10.1093.
    PubMed     Abstract available


  98. MUHR LSA, Eklund C, Lagheden C, Eriksson T, et al
    Head-to-head comparison of bi- and nonavalent human papillomavirus vaccine-induced antibody responses.
    J Infect Dis. 2022 May 10. pii: 6582940. doi: 10.1093.
    PubMed     Abstract available


  99. LIU B, Stepien S, Pye V, Law C, et al
    High attack rate of SARS-CoV-2 B.1.1.529 among two-dose vaccinated populations in two indoor entertainment setting outbreaks.
    J Infect Dis. 2022 May 7. pii: 6582820. doi: 10.1093.
    PubMed     Abstract available


  100. KURAHASHI Y, Furukawa K, Sutandhio S, Tjan LH, et al
    Cross-neutralizing activity against Omicron could be obtained in SARS-CoV-2 convalescent patients who received two doses of mRNA vaccination.
    J Infect Dis. 2022 May 5. pii: 6580685. doi: 10.1093.
    PubMed     Abstract available


  101. MITSI E, McLenaghan D, Wolf AS, Jones S, et al
    Thirteen-Valent Pneumococcal Conjugate Vaccine-Induced Immunoglobulin G (IgG) Responses in Serum Associated With Serotype-Specific IgG in the Lung.
    J Infect Dis. 2022;225:1626-1631.
    PubMed     Abstract available


  102. SIRIVICHAYAKUL C, Barranco-Santana EA, Rivera IE, Kilbury J, et al
    Long-term Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Children and Adults: A Randomized, Placebo-Controlled, Phase 2 Study.
    J Infect Dis. 2022;225:1513-1520.
    PubMed     Abstract available


    April 2022
  103. SMID M, Berec L, Pribylova L, Majek O, et al
    Protection by vaccines and previous infection against the Omicron variant of SARS-CoV-2.
    J Infect Dis. 2022 Apr 28. pii: 6575414. doi: 10.1093.
    PubMed     Abstract available


  104. TJAN LH, Furukawa K, Kurahashi Y, Sutandhio S, et al
    As well as Omicron BA.1, high neutralizing activity against Omicron BA.2 can be induced by COVID-19 mRNA booster vaccination.
    J Infect Dis. 2022 Apr 28. pii: 6575227. doi: 10.1093.
    PubMed    


  105. BAJEMA KL, Gierke R, Farley MM, Schaffner W, et al
    Impact of Pneumococcal Conjugate Vaccines on Antibiotic-Nonsusceptible Invasive Pneumococcal Disease in the United States.
    J Infect Dis. 2022 Apr 28. pii: 6575225. doi: 10.1093.
    PubMed     Abstract available


  106. ASSAWAKOSRI S, Kanokudom S, Suntronwong N, Puenpa J, et al
    Omicron BA.1, BA.2 and COVID-19 booster vaccination.
    J Infect Dis. 2022 Apr 27. pii: 6575160. doi: 10.1093.
    PubMed    


  107. OKUDA M, Sakai-Tagawa Y, Koga M, Koibuchi T, et al
    Immunological correlates of prevention of the onset of seasonal H3N2 influenza.
    J Infect Dis. 2022 Apr 27. pii: 6574940. doi: 10.1093.
    PubMed     Abstract available


  108. LIN DY, Zeng D, Gu Y, Krause PR, et al
    Reliably Assessing Duration of Protection for COVID-19 Vaccines.
    J Infect Dis. 2022 Apr 21. pii: 6571630. doi: 10.1093.
    PubMed     Abstract available


  109. SKOWRONSKI DM, Leir S, Sabaiduc S, Chambers C, et al
    Influenza Vaccine Effectiveness by A(H3N2) Phylogenetic Subcluster and Prior Vaccination History: 2016-2017 and 2017-2018 Epidemics in Canada.
    J Infect Dis. 2022;225:1387-1398.
    PubMed     Abstract available


  110. BROKAW A, Nguyen S, Quach P, Orvis A, et al
    A recombinant alpha-like protein subunit vaccine (GBS-NN) provides protection in murine models of Group B Streptococcus infection.
    J Infect Dis. 2022 Apr 16. pii: 6569354. doi: 10.1093.
    PubMed     Abstract available


  111. ZHU KL, Gao HX, Yao L, Rong J, et al
    Delta infection following vaccination elicits potent neutralizing immunity against the SARS-CoV-2 Omicron.
    J Infect Dis. 2022 Apr 16. pii: 6569353. doi: 10.1093.
    PubMed     Abstract available


  112. LE GARS M, Sadoff J, Struyf F, Heerwegh D, et al
    Impact of preexisting anti-Ad26 humoral immunity on immunogenicity of the Ad26.COV2.S COVID-19 vaccine.
    J Infect Dis. 2022 Apr 16. pii: 6569363. doi: 10.1093.
    PubMed     Abstract available


  113. BOLOTIN S, Osman S, Hughes SL, Ariyarajah A, et al
    In Elimination Settings, Measles Antibodies Wane Following Vaccination but Not Following Infection - A Systematic Review and Meta-Analysis.
    J Infect Dis. 2022 Apr 13. pii: 6568034. doi: 10.1093.
    PubMed     Abstract available


  114. PERMAR SR, Kaur A, Fruh K
    De-risking human cytomegalovirus vaccine clinical development in relevant preclinical models.
    J Infect Dis. 2022 Apr 13. pii: 6567687. doi: 10.1093.
    PubMed    


  115. LI J, Wellnitz S, Chi XS, Yue Y, et al
    Horizontal transmission of cytomegalovirus in a rhesus model despite high-level, vaccine-elicited neutralizing antibody and T cell responses.
    J Infect Dis. 2022 Apr 12. pii: 6567520. doi: 10.1093.
    PubMed     Abstract available


  116. KWON JH, Tenforde MW, Gaglani M, Talbot HK, et al
    mRNA Vaccine Effectiveness Against COVID-19 Hospitalization Among Solid Organ Transplant Recipients.
    J Infect Dis. 2022 Apr 6. pii: 6564370. doi: 10.1093.
    PubMed     Abstract available


  117. XIONG W, Tsang TK, Perera RAPM, Leung NHL, et al
    Biphasic waning of hemagglutination inhibition antibody titers after influenza vaccination in children.
    J Infect Dis. 2022 Apr 5. pii: 6563665. doi: 10.1093.
    PubMed     Abstract available


  118. CARR OJJ, Vilivong K, Bounvilay L, Dunne EM, et al
    Nasopharyngeal Pneumococcal Colonization Density Is Associated With Severe Pneumonia in Young Children in the Lao People's Democratic Republic.
    J Infect Dis. 2022;225:1266-1273.
    PubMed     Abstract available


    March 2022
  119. ITSKO M, Topaz N, Ousmane S, Popoola M, et al
    Enhancing meningococcal genomic surveillance in the meningitis belt using high-resolution culture-free whole genome sequencing.
    J Infect Dis. 2022 Mar 24. pii: 6553907. doi: 10.1093.
    PubMed     Abstract available


  120. MARON JS, Conroy M, Naranbai V, Samarakoon U, et al
    Differential SARS-CoV-2 Antibody Profiles after Allergic Reactions to mRNA COVID-19 Vaccine.
    J Infect Dis. 2022 Mar 23. pii: 6553054. doi: 10.1093.
    PubMed     Abstract available


  121. RIEKE GJ, van Bremen K, Bischoff J, To Vinh M, et al
    Induction of NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC) against SARS-CoV-2 after natural infection is more potent than after vaccination.
    J Infect Dis. 2022 Mar 22. pii: 6552258. doi: 10.1093.
    PubMed     Abstract available


  122. LEWNARD JA, Bruxvoort KJ, Hong VX, Grant LR, et al
    Effectiveness of pneumococcal conjugate vaccination against virus-associated lower respiratory tract infection among adults: a case-control study.
    J Infect Dis. 2022 Mar 22. pii: 6552253. doi: 10.1093.
    PubMed     Abstract available


  123. LI X, Bilcke J, Vazquez Fernandez L, Bont L, et al
    Cost-effectiveness of Respiratory Syncytial Virus Disease Prevention Strategies: Maternal Vaccine Versus Seasonal or Year-Round Monoclonal Antibody Program in Norwegian Children.
    J Infect Dis. 2022 Mar 16. pii: 6549175. doi: 10.1093.
    PubMed     Abstract available


  124. ROHRIG A, Eyal N
    The Ethics of Human Challenge Trials Using Emerging Severe Acute Respiratory Syndrome 2 Variants.
    J Infect Dis. 2022;225:934-937.
    PubMed     Abstract available


  125. ASSAWAKOSRI S, Kanokudom S, Suntronwong N, Auphimai C, et al
    Neutralizing Activities against the Omicron Variant after a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination.
    J Infect Dis. 2022 Mar 10. pii: 6546425. doi: 10.1093.
    PubMed     Abstract available


  126. HALL EW, Weng MK, Harris AM, Schillie S, et al
    Assessing the cost-utility of universal hepatitis B vaccination among adults.
    J Infect Dis. 2022 Mar 9. pii: 6545195. doi: 10.1093.
    PubMed     Abstract available


  127. SANTONJA I, Stiasny K, Essl A, Heinz FX, et al
    Tick-borne encephalitis in vaccinated patients: a retrospective case-control study and analysis of vaccination field effectiveness in Austria from 2000 to 2018.
    J Infect Dis. 2022 Mar 2. pii: 6541329. doi: 10.1093.
    PubMed     Abstract available


    February 2022
  128. MORITZKY SA, Richards KA, Glover MA, Krammer F, et al
    The negative effect of pre-existing immunity on influenza vaccine responses transcends the impact of vaccine formulation type and vaccination history.
    J Infect Dis. 2022 Feb 24. pii: 6535476. doi: 10.1093.
    PubMed     Abstract available


  129. BELSHE RB, Blevins TP, Yu Y, Nethington AE, et al
    Neutralizing Antibody Kinetics and Immune Protection Against HSV-1 Genital Disease in Vaccinated Women.
    J Infect Dis. 2022 Feb 24. pii: 6535411. doi: 10.1093.
    PubMed     Abstract available


  130. LENTSCHER AJ, McAllister N, Griswold KA, Martin JL, et al
    Chikungunya virus vaccine candidate incorporating synergistic mutations is attenuated and protects against virulent virus challenge.
    J Infect Dis. 2022 Feb 23. pii: 6535121. doi: 10.1093.
    PubMed     Abstract available


  131. BURNETT E, Parashar UD, Winn A, Tate JE, et al
    Trends in rotavirus laboratory detections and internet search volume before and after rotavirus vaccine introduction and in the context of the COVID-19 pandemic-- United States 2000-2021.
    J Infect Dis. 2022 Feb 20. pii: 6532606. doi: 10.1093.
    PubMed     Abstract available


  132. HARALAMBIEVA IH, Monroe JM, Ovsyannikova IG, Grill DE, et al
    Distinct Homologous and Variant-Specific Memory B-Cell and Antibody Response Over Time after SARS-CoV-2 mRNA Vaccination.
    J Infect Dis. 2022 Feb 8. pii: 6524526. doi: 10.1093.
    PubMed     Abstract available


  133. KIM N, Shin S, Minn D, Park S, et al
    SARS-CoV-2 Infectivity and Antibody Titer Reduction for 6 Months After Second Dose of BNT162b2 mRNA Vaccine in Healthcare Workers: A Prospective Cohort Study.
    J Infect Dis. 2022 Feb 1. pii: 6519374. doi: 10.1093.
    PubMed     Abstract available


  134. RYAN KA, Schewe KE, Crowe J, Fotheringham SA, et al
    Sequential Delivery of Live Attenuated Influenza Vaccine and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in the Ferret Model Can Reduce SARS-CoV-2 Shedding and Does Not Result in Enhanced Lung Pathology.
    J Infect Dis. 2022;225:404-412.
    PubMed     Abstract available


    January 2022
  135. SPENGLER JR, Kainulainen MH, Welch SR, Coleman-McCray JAD, et al
    Lassa virus replicon particle vaccine protects strain 13/N guinea pigs against challenge with geographically and genetically diverse viral strains.
    J Infect Dis. 2022 Jan 31. pii: 6517689. doi: 10.1093.
    PubMed     Abstract available


  136. SKOWRONSKI DM, Setayeshgar S, Zou M, Prystajecky N, et al
    Comparative single-dose mRNA and ChAdOx1 vaccine effectiveness against SARS-CoV-2, including variants of concern: test-negative design, British Columbia, Canada.
    J Infect Dis. 2022 Jan 27. pii: 6515934. doi: 10.1093.
    PubMed     Abstract available


  137. KRAYNYAK KA, Blackwood E, Agnes J, Tebas P, et al
    SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial.
    J Infect Dis. 2022 Jan 25. pii: 6515374. doi: 10.1093.
    PubMed     Abstract available


  138. GUAN M, Johannesen E, Tang CY, Hsu AL, et al
    Intrauterine fetal demise in the third trimester of pregnancy associated with mild infection with the SARS-CoV-2 Delta variant without protection from vaccination.
    J Infect Dis. 2022 Jan 13. pii: 6506263. doi: 10.1093.
    PubMed     Abstract available


  139. KRISTENSEN JH, Hasselbalch RB, Pries-Heje M, Nielsen PB, et al
    Effect of influenza vaccination on risk of COVID-19 - A prospective cohort study of 46,000 health care workers.
    J Infect Dis. 2022 Jan 5. pii: 6497955. doi: 10.1093.
    PubMed     Abstract available


  140. CHU VT, Simon E, Lu X, Rockwell P, et al
    Outbreak of Acute Respiratory Illness Associated With Human Adenovirus Type 4 at the United States Coast Guard Academy, 2019.
    J Infect Dis. 2022;225:55-64.
    PubMed     Abstract available


    December 2021
  141. LEWIS LA, Gulati S, Zelek WM, Morgan BP, et al
    Efficacy of an experimental gonococcal lipooligosaccharide mimitope vaccine requires terminal complement.
    J Infect Dis. 2021 Dec 31. pii: 6491069. doi: 10.1093.
    PubMed     Abstract available


  142. LUCZKOWIAK J, Labiod N, Rivas G, Rolo M, et al
    Neutralizing response against SARS-CoV-2 variants 8 months after BNT162b2 vaccination in naive and COVID-19 convalescent individuals.
    J Infect Dis. 2021 Dec 28. pii: 6486499. doi: 10.1093.
    PubMed     Abstract available


  143. BRUXVOORT KJ, Ackerson B, Sy LS, Bhavsar A, et al
    Recombinant adjuvanted zoster vaccine and reduced risk of COVID-19 diagnosis and hospitalization in older adults.
    J Infect Dis. 2021 Dec 28. pii: 6486498. doi: 10.1093.
    PubMed     Abstract available


  144. LIU J, Huang B, Li G, Chang X, et al
    Immunogenicity and Safety of a Three-Dose Regimen of a SARS-CoV-2 Inactivated Vaccine in Adults: A Randomized, Double-blind, Placebo-controlled Phase 2 Trial.
    J Infect Dis. 2021 Dec 27. pii: 6484920. doi: 10.1093.
    PubMed     Abstract available


  145. ABARA WE, Gee J, Delorey M, Tun Y, et al
    Expected Rates of Select Adverse Events following Immunization for COVID-19 Vaccine Safety Monitoring.
    J Infect Dis. 2021 Dec 27. pii: 6484617. doi: 10.1093.
    PubMed     Abstract available


  146. KIM SS, Naioti EA, Halasa NB, Stewart LS, et al
    Vaccine Effectiveness against Influenza Hospitalization and Emergency Department Visits in Two A(H3N2) Dominant Influenza Seasons among Children <18 Years Old, New Vaccine Surveillance Network 2016-17 and 2017-18.
    J Infect Dis. 2021 Dec 24. pii: 6482612. doi: 10.1093.
    PubMed     Abstract available


  147. PHIJFFER EWEM, Bont LJ
    Are we ready for maternal RSV vaccination?
    J Infect Dis. 2021 Dec 21. pii: 6472740. doi: 10.1093.
    PubMed    


  148. LEWIS NM, Naioti EA, Self WH, Ginde AA, et al
    Effectiveness of mRNA vaccines in preventing COVID-19 hospitalization by age and burden of chronic medical conditions among immunocompetent US adults, March-August 2021.
    J Infect Dis. 2021 Dec 21. pii: 6472998. doi: 10.1093.
    PubMed     Abstract available


  149. WALSH EE, Falsey AR, Scott DA, Gurtman A, et al
    A Randomized Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine.
    J Infect Dis. 2021 Dec 21. pii: 6472747. doi: 10.1093.
    PubMed     Abstract available


  150. FALSEY AR, Walsh EE, Scott DA, Gurtman A, et al
    Phase 1/2 Randomized Study of the Immunogenicity, Safety and Tolerability of an RSV Prefusion F Vaccine in Adults With Concomitant Inactivated Influenza Vaccine.
    J Infect Dis. 2021 Dec 21. pii: 6472733. doi: 10.1093.
    PubMed     Abstract available


  151. IYER AS, Harris JB
    Correlates of Protection for Cholera.
    J Infect Dis. 2021;224.
    PubMed     Abstract available


  152. SAHA GK, Ganguly NK
    Spread and Endemicity of Cholera in India: Factors Beyond the Numbers.
    J Infect Dis. 2021;224.
    PubMed     Abstract available


  153. CHAO DL
    Mathematical Modeling of Endemic Cholera Transmission.
    J Infect Dis. 2021;224.
    PubMed     Abstract available


  154. SACK DA, Debes AK, Ateudjieu J, Bwire G, et al
    Contrasting Epidemiology of Cholera in Bangladesh and Africa.
    J Infect Dis. 2021;224.
    PubMed     Abstract available


  155. FLECKENSTEIN JM, Sheikh A
    Emerging Themes in the Molecular Pathogenesis of Enterotoxigenic Escherichia coli.
    J Infect Dis. 2021;224.
    PubMed     Abstract available


  156. BRUNHAM RC
    Problems with Understanding Chlamydia trachomatis Immunology.
    J Infect Dis. 2021 Dec 17. pii: 6469012. doi: 10.1093.
    PubMed     Abstract available


  157. HASTIE A, Catteau G, Enemuo A, Mrkvan T, et al
    Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine: Persistence and Anamnestic Response to Additional Doses Administered 10 Years After Primary Vaccination.
    J Infect Dis. 2021;224:2025-2034.
    PubMed     Abstract available


  158. HUI BB, Padeniya TN, Rebuli N, Gray RT, et al
    A gonococcal vaccine has the potential to rapidly reduce the incidence of Neisseria gonorrhoeae infection among urban men who have sex with men.
    J Infect Dis. 2021 Dec 11. pii: 6459455. doi: 10.1093.
    PubMed     Abstract available


  159. CHRISTENSEN H, Vickerman P
    Gonococcal vaccines for controlling Neisseria gonorrhoeae in men who have sex with men: a promising game-changer.
    J Infect Dis. 2021 Dec 11. pii: 6459454. doi: 10.1093.
    PubMed    


  160. BROCKMAN MA, Mwimanzi F, Lapointe HR, Sang Y, et al
    Reduced magnitude and durability of humoral immune responses to COVID-19 mRNA vaccines among older adults.
    J Infect Dis. 2021 Dec 9. pii: 6458430. doi: 10.1093.
    PubMed     Abstract available


  161. NARANBHAI V, Garcia-Beltran WF, Chang CC, Mairena CB, et al
    Comparative immunogenicity and effectiveness of mRNA-1273, BNT162b2 and Ad26.COV2.S COVID-19 vaccines.
    J Infect Dis. 2021 Dec 9. pii: 6458467. doi: 10.1093.
    PubMed     Abstract available


    November 2021
  162. GILBOA M, Mandelboim M, Indenbaum V, Lustig Y, et al
    Early Immunogenicity and safety of the third dose of BNT162b2 mRNA Covid-19 vaccine among adults older than 60 years; real world experience.
    J Infect Dis. 2021 Nov 29. pii: 6446235. doi: 10.1093.
    PubMed     Abstract available


  163. JOHNSON MJ, Liu C, Ghosh D, Lang N, et al
    Cell-Mediated Immune Responses After Administration Of The Live Or The Recombinant Zoster Vaccine: Five-Year Persistence.
    J Infect Dis. 2021 Nov 27. pii: 6444689. doi: 10.1093.
    PubMed     Abstract available


  164. KIM JY, Lim SY, Park S, Kwon JS, et al
    Immune responses to the ChAdOx1 nCoV-19 and BNT162b2 vaccines and to natural COVID-19 infections over a three-month period.
    J Infect Dis. 2021 Nov 25. pii: 6440288. doi: 10.1093.
    PubMed     Abstract available


  165. RYCKMAN T, Karthikeyan AS, Kumar D, Cao Y, et al
    Comparison of Strategies for Typhoid Conjugate Vaccine Introduction in India: A Cost-Effectiveness Modeling Study.
    J Infect Dis. 2021;224.
    PubMed     Abstract available


  166. KUMAR S, Ghosh RS, Iyer H, Ray A, et al
    Typhoid in India: An Age-old Problem With an Existing Solution.
    J Infect Dis. 2021;224.
    PubMed     Abstract available


  167. CAO Y, Karthikeyan AS, Ramanujam K, Raju R, et al
    Geographic Pattern of Typhoid Fever in India: A Model-Based Estimate of Cohort and Surveillance Data.
    J Infect Dis. 2021;224.
    PubMed     Abstract available


  168. SINHA B, Rongsen-Chandola T, Goyal N, Arya A, et al
    Incidence of Enteric Fever in a Pediatric Cohort in North India: Comparison with Estimates from 20 Years Earlier.
    J Infect Dis. 2021;224.
    PubMed     Abstract available


  169. MOHAN VR, Srinivasan M, Sinha B, Shrivastava A, et al
    Geographically Weighted Regression Modeling of Spatial Clustering and Determinants of Focal Typhoid Fever Incidence.
    J Infect Dis. 2021;224.
    PubMed     Abstract available


  170. AMBROSINO D, Han HH, Hu B, Liang J, et al
    Immunogenicity of SCB-2019 Coronavirus Disease 2019 Vaccine Compared With 4 Approved Vaccines.
    J Infect Dis. 2021 Nov 19. pii: 6431853. doi: 10.1093.
    PubMed     Abstract available


  171. FULDA ES, Fitch KV, Overton ET, Zanni MV, et al
    COVID-19 Vaccination Rates in a Global HIV Cohort.
    J Infect Dis. 2021 Nov 18. pii: 6431673. doi: 10.1093.
    PubMed     Abstract available


  172. COLLIER AY, Yu J, Mcmahan K, Liu J, et al
    COVID-19 mRNA Vaccine Immunogenicity in Immunosuppressed Individuals.
    J Infect Dis. 2021 Nov 18. pii: 6430790. doi: 10.1093.
    PubMed     Abstract available


  173. ALAM MM, Ikram A, Mahmood N, Sharif S, et al
    Antigenic structure of wild poliovirus type 1 strains endemic in Pakistan is highly conserved and completely neutralized by Sabin's Oral Polio Vaccine.
    J Infect Dis. 2021 Nov 17. pii: 6430438. doi: 10.1093.
    PubMed     Abstract available


  174. DUARTE G, Muresan P, Ward S, Laimon L, et al
    Immunogenicity of conjugated and polysaccharide pneumococcal vaccines administered during pregnancy or postpartum to women with HIV.
    J Infect Dis. 2021 Nov 16. pii: 6429421. doi: 10.1093.
    PubMed     Abstract available


  175. BIERLE DM, Ganesh R, Tulledge-Scheitel S, Hanson SN, et al
    Monoclonal Antibody Treatment of Breakthrough COVID-19 in Fully Vaccinated Individuals with High-Risk Comorbidities.
    J Infect Dis. 2021 Nov 16. pii: 6429422. doi: 10.1093.
    PubMed     Abstract available


  176. JOHNSON S, Martinez CI, Tedjakusuma SN, Peinovich N, et al
    Oral vaccination protects against SARS-CoV-2 in a Syrian hamster challenge model.
    J Infect Dis. 2021 Nov 10. pii: 6425228. doi: 10.1093.
    PubMed     Abstract available


  177. STOCKDALE AJ, Meiring JE, Shawa IT, Thindwa D, et al
    Hepatitis B vaccination impact and the unmet need for antiviral treatment in Blantyre, Malawi.
    J Infect Dis. 2021 Nov 9. pii: 6424415. doi: 10.1093.
    PubMed     Abstract available


  178. FERREIRA VH, Marinelli T, Ierullo M, Ku T, et al
    SARS-CoV-2 infection induces greater T-cell responses compared to vaccination in solid organ transplant recipients.
    J Infect Dis. 2021 Nov 5. pii: 6406613. doi: 10.1093.
    PubMed     Abstract available


  179. SACIUK Y, Kertes J, Shamir Stein N, Ekka Zohar A, et al
    Effectiveness of a third dose of BNT162b2 mRNA vaccine.
    J Infect Dis. 2021 Nov 2. pii: 6415586. doi: 10.1093.
    PubMed     Abstract available


    October 2021
  180. MEIJIDE MIGUEZ H, Ochando Gomez M, Montes Garcia I, Garcia Merino IM, et al
    Cellular and humoral response, six months after two doses of BNT162b2 mRNA Covid 19 vaccination, in residents and staff of nursing homes for the elderly.
    J Infect Dis. 2021 Oct 28. pii: 6413766. doi: 10.1093.
    PubMed    


  181. CHAKRABORTY D, Kanungo S, Nandy RK, Deb AK, et al
    Challenges for Programmatic Implementation of Oral Cholera Vaccine in India.
    J Infect Dis. 2021 Oct 20. pii: 6404482. doi: 10.1093.
    PubMed     Abstract available


  182. CALLEGARO A, Burny W, Herve C, Kim JH, et al
    Association between immunogenicity and reactogenicity: a post hoc analysis of two Phase 3 studies with the adjuvanted recombinant zoster vaccine.
    J Infect Dis. 2021 Oct 18. pii: 6400271. doi: 10.1093.
    PubMed     Abstract available


  183. WITHANAGE K, De Coster I, Cools N, Viviani S, et al
    Phase 1 randomized, placebo-controlled, dose-escalating study to evaluate OVX836, a nucleoprotein-based influenza vaccine: intramuscular results.
    J Infect Dis. 2021 Oct 15. pii: 6398205. doi: 10.1093.
    PubMed     Abstract available


  184. PRENTICE S, Dockrell HM
    BCG Specific and Nonspecific Effects: Different Questions, Similar Challenges.
    J Infect Dis. 2021;224:1105-1108.
    PubMed    


  185. WILLIAMS FB, Kader A, Colgate ER, Dickson DM, et al
    Maternal Secretor Status Affects Oral Rotavirus Vaccine Response in Breastfed Infants in Bangladesh.
    J Infect Dis. 2021;224:1147-1151.
    PubMed     Abstract available


  186. DAGNEW AF, Klein NP, Herve C, Kalema G, et al
    The Adjuvanted Recombinant Zoster Vaccine in Adults Aged >/=65 Years Previously Vaccinated With a Live-Attenuated Herpes Zoster Vaccine.
    J Infect Dis. 2021;224:1139-1146.
    PubMed     Abstract available


  187. PETERSON JT, Zareba AM, Fitz-Patrick D, Essink BJ, et al
    Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F Vaccine When Co-Administered With a Tetanus, Diphtheria, and Acellular Pertussis Vaccine.
    J Infect Dis. 2021 Oct 12. pii: 6391485. doi: 10.1093.
    PubMed     Abstract available


  188. DILLER JR, Carter MH, Kanai Y, Sanchez SV, et al
    Monoreassortant rotaviruses of multiple G types are differentially neutralized by sera from infants vaccinated with ROTARIX(R) and RotaTeq(R).
    J Infect Dis. 2021 Oct 10. pii: 6386353. doi: 10.1093.
    PubMed     Abstract available


  189. DODD RY, Notari EP, Brodsky JP, Foster GA, et al
    Patterns of antibody response to SARS-CoV-2 among 1.6 million blood donors: Impact of vaccination, United States December 2020 - June 2021.
    J Infect Dis. 2021 Oct 9. pii: 6385747. doi: 10.1093.
    PubMed     Abstract available


  190. LU Y, Jiao Y, Graham DJ, Wu Y, et al
    Risk factors for COVID-19 deaths among elderly nursing home Medicare beneficiaries in the pre-vaccine period.
    J Infect Dis. 2021 Oct 7. pii: 6383455. doi: 10.1093.
    PubMed     Abstract available


  191. GAST C, Bandyopadhyay AS, Saez-Llorens X, De Leon T, et al
    Fecal shedding of two novel live attenuated oral poliovirus type 2 vaccines candidates by healthy bOPV/IPV-vaccinated infants: two randomized clinical trials.
    J Infect Dis. 2021 Oct 5. pii: 6381642. doi: 10.1093.
    PubMed     Abstract available


  192. GERSHON AA, Gershon MD
    Widespread use of varicella vaccine does not reduce immunity to zoster of others.
    J Infect Dis. 2021 Oct 5. pii: 6381628. doi: 10.1093.
    PubMed    


  193. CARRYN S, Cheuvart B, Povey M, Dagnew AF, et al
    No consistent evidence of decreased exposure to varicella-zoster virus among older adults in countries with universal varicella vaccination.
    J Infect Dis. 2021 Oct 5. pii: 6381619. doi: 10.1093.
    PubMed     Abstract available


    September 2021
  194. GLASS RI, Tate JE, Jiang B, Parashar U, et al
    The Rotavirus Vaccine Story: From Discovery to the Eventual Control of Rotavirus Disease.
    J Infect Dis. 2021;224.
    PubMed     Abstract available


  195. MARKOWITZ LE, Schiller JT
    Human Papillomavirus Vaccines.
    J Infect Dis. 2021;224.
    PubMed     Abstract available


  196. GERSHON AA, Gershon MD, Shapiro ED
    Live Attenuated Varicella Vaccine: Prevention of Varicella and of Zoster.
    J Infect Dis. 2021;224.
    PubMed     Abstract available


  197. BECKER T, Elbahesh H, Reperant LA, Rimmelzwaan GF, et al
    Influenza Vaccines: Successes and Continuing Challenges.
    J Infect Dis. 2021;224.
    PubMed     Abstract available


  198. PATTYN J, Hendrickx G, Vorsters A, Van Damme P, et al
    Hepatitis B Vaccines.
    J Infect Dis. 2021;224.
    PubMed     Abstract available


  199. RODGERS GL, Whitney CG, Klugman KP
    Triumph of Pneumococcal Conjugate Vaccines: Overcoming a Common Foe.
    J Infect Dis. 2021;224.
    PubMed     Abstract available


  200. HARBECKE R, Cohen JI, Oxman MN
    Herpes Zoster Vaccines.
    J Infect Dis. 2021;224.
    PubMed     Abstract available


  201. GILSDORF JR
    Hib Vaccines: Their Impact on Haemophilus influenzae Type b Disease.
    J Infect Dis. 2021;224.
    PubMed     Abstract available


  202. BREMAN JG
    Smallpox.
    J Infect Dis. 2021;224.
    PubMed    


  203. MODLIN JF, Bandyopadhyay AS, Sutter R
    Immunization Against Poliomyelitis and the Challenges to Worldwide Poliomyelitis Eradication.
    J Infect Dis. 2021;224.
    PubMed     Abstract available


  204. PLOTKIN SA
    Rubella Eradication: Not Yet Accomplished, but Entirely Feasible.
    J Infect Dis. 2021;224.
    PubMed     Abstract available


  205. DECKER MD, Edwards KM
    Pertussis (Whooping Cough).
    J Infect Dis. 2021;224.
    PubMed     Abstract available


  206. GASTANADUY PA, Goodson JL, Panagiotakopoulos L, Rota PA, et al
    Measles in the 21st Century: Progress Toward Achieving and Sustaining Elimination.
    J Infect Dis. 2021;224.
    PubMed     Abstract available


  207. KARBIENER M, Farcet MR, Schwaiger J, Powers N, et al
    Plasma from post-COVID-19 and COVID-19-Vaccinated Donors Results in Highly Potent SARS-CoV-2 Neutralization by Intravenous Immunoglobulins.
    J Infect Dis. 2021 Sep 20. pii: 6372887. doi: 10.1093.
    PubMed     Abstract available


  208. FERREIRA IATM, Kemp SA, Datir R, Saito A, et al
    SARS-CoV-2 B.1.617 Mutations L452R and E484Q Are Not Synergistic for Antibody Evasion.
    J Infect Dis. 2021;224:989-994.
    PubMed     Abstract available


  209. PROBERT WS, Glenn-Finer R, Espinosa A, Yen C, et al
    Molecular Epidemiology of Measles in California, United States-2019.
    J Infect Dis. 2021;224:1015-1023.
    PubMed     Abstract available


  210. GORSE GJ, Rattigan SM, Kirpich A, Simberkoff MS, et al
    Influence of Pre-Season Antibodies against Influenza Virus on Risk of Influenza Infection among Health Care Personnel.
    J Infect Dis. 2021 Sep 17. pii: 6371937. doi: 10.1093.
    PubMed     Abstract available


  211. VAN PRAET JT, Vandecasteele S, De Roo A, Vynck M, et al
    Dynamics of the cellular and humoral immune response after BNT162b2 mRNA Covid-19 vaccination in Covid-19 naive nursing home residents.
    J Infect Dis. 2021 Sep 13. pii: 6369254. doi: 10.1093.
    PubMed     Abstract available


  212. KIM SS, Chung JR, Belongia EA, McLean HQ, et al
    mRNA Vaccine Effectiveness against COVID-19 among Symptomatic Outpatients Aged >/=16 Years in the United States, February - May 2021.
    J Infect Dis. 2021 Sep 8. pii: 6366365. doi: 10.1093.
    PubMed     Abstract available


  213. RICHMOND PC, Hatchuel L, Pacciarini F, Hu B, et al
    Persistence of the immune responses and cross-neutralizing activity with Variants of Concern following two doses of adjuvanted SCB-2019 COVID-19 vaccine.
    J Infect Dis. 2021 Sep 4. pii: 6364149. doi: 10.1093.
    PubMed     Abstract available


  214. DU PLESSIS M, de Gouveia L, Freitas C, Abera NA, et al
    The Role of Molecular Testing in Pediatric Meningitis Surveillance in Southern and East African Countries, 2008-2017.
    J Infect Dis. 2021;224.
    PubMed     Abstract available


    August 2021
  215. GIURGEA LT, Cervantes-Medina A, Walters KA, Scherler K, et al
    Sex Differences in Influenza: The Challenge Study Experience.
    J Infect Dis. 2021 Aug 23. pii: 6356350. doi: 10.1093.
    PubMed     Abstract available


  216. MAN I, Vanska S, Lehtinen M, Bogaards JA, et al
    Human Papillomavirus Genotype Replacement: Still Too Early to Tell?
    J Infect Dis. 2021;224:481-491.
    PubMed     Abstract available


    June 2021
  217. WHITEHOUSE ER, Bonwitt J, Hughes CM, Lushima RS, et al
    Clinical and Epidemiological Findings from Enhanced Monkeypox Surveillance in Tshuapa Province, Democratic Republic of the Congo During 2011-2015.
    J Infect Dis. 2021;223:1870-1878.
    PubMed     Abstract available


    April 2021
  218. WILHELM M, Kaur A, Wernli M, Hirsch HH, et al
    BK Polyomavirus-Specific CD8 T-Cell Expansion In Vitro Using 27mer Peptide Antigens for Developing Adoptive T-Cell Transfer and Vaccination.
    J Infect Dis. 2021;223:1410-1422.
    PubMed     Abstract available


  219. EL SAHLY HM, Atmar RL, Sendra E, Wegel A, et al
    Topical Imiquimod Does not Provide an Adjuvant Effect when Administered with Inactivated Influenza A/H5N1 Vaccine in Healthy Young Adults.
    J Infect Dis. 2021 Apr 14. pii: 6225864. doi: 10.1093.
    PubMed     Abstract available


  220. BLUMENFELD O, Hampe CS, Shulman LM, Chen R, et al
    An Attenuation in the Incidence of Early Childhood Diabetes Correlates With Introduction of Rotavirus Vaccination in Israel.
    J Infect Dis. 2021;223:1305-1307.
    PubMed    


  221. SALEEM AF, Mach O, Yousafzai MT, Kazi Z, et al
    One-Year Decline of Poliovirus Antibodies Following Fractional-Dose Inactivated Poliovirus Vaccine.
    J Infect Dis. 2021;223:1214-1221.
    PubMed     Abstract available


  222. BEALL B, Walker H, Tran T, Li Z, et al
    Upsurge of Conjugate Vaccine Serotype 4 Invasive Pneumococcal Disease Clusters Among Adults Experiencing Homelessness in California, Colorado, and New Mexico.
    J Infect Dis. 2021;223:1241-1249.
    PubMed     Abstract available


  223. RAMAN R, Brennan J, Ndi D, Sloan C, et al
    Marked Reduction of Socioeconomic and Racial Disparities in Invasive Pneumococcal Disease Associated With Conjugate Pneumococcal Vaccines.
    J Infect Dis. 2021;223:1250-1259.
    PubMed     Abstract available


  224. WAGSTAFFE HR, Clutterbuck EA, Bockstal V, Stoop JN, et al
    Antibody-Dependent Natural Killer Cell Activation After Ebola Vaccination.
    J Infect Dis. 2021;223:1171-1182.
    PubMed     Abstract available


    March 2021
  225. JORDAN E, Lawrence SJ, Meyer TPH, Schmidt D, et al
    Broad Antibody and Cellular Immune Response From a Phase 2 Clinical Trial With a Novel Multivalent Poxvirus-Based Respiratory Syncytial Virus Vaccine.
    J Infect Dis. 2021;223:1062-1072.
    PubMed     Abstract available


    January 2021
  226. DE PIJPER CA, Langedijk AC, Terryn S, Van Gucht S, et al
    Long-term memory response after a single intramuscular rabies booster vaccination, 10-24 years after primary immunization.
    J Infect Dis. 2021 Jan 27. pii: 6121364. doi: 10.1093.
    PubMed     Abstract available


    September 2020
  227. TOTA JE, Struyf F, Hildesheim A, Gonzalez P, et al
    Efficacy of AS04-adjuvanted HPV-16/18 vaccine against clearance of incident HPV infections: Pooled analysis of data from the CVT and PATRICIA randomized trials.
    J Infect Dis. 2020 Sep 5. pii: 5901687. doi: 10.1093.
    PubMed     Abstract available


    August 2020
  228. SADOFF J, De Paepe E, Haazen W, Omoruyi E, et al
    Safety and Immunogenicity of the Ad26.RSV.preF Investigational Vaccine Coadministered With an Influenza Vaccine in Older Adults.
    J Infect Dis. 2020 Aug 26. pii: 5897745. doi: 10.1093.
    PubMed     Abstract available


  229. PANG Y, Wang Q, Lv M, Yu M, et al
    Influenza vaccination protects against hospitalization outcomes among older patients with cardiovascular or respiratory diseases.
    J Infect Dis. 2020 Aug 11. pii: 5890841. doi: 10.1093.
    PubMed     Abstract available


    July 2020
  230. CAMPBELL N, Verrall AJ, Donkor S, Sutherland JS, et al
    BCG protection against Mycobacterium tuberculosis infection by level of exposure in The Gambia.
    J Infect Dis. 2020 Jul 8. pii: 5868549. doi: 10.1093.
    PubMed     Abstract available


  231. HU SY, Tsang SH, Chen F, Pan QJ, et al
    Association between Common Vaginal Infections and Cervical Non-HPV16/18 Infection in HPV-Vaccinated Women.
    J Infect Dis. 2020 Jul 2. pii: 5866538. doi: 10.1093.
    PubMed     Abstract available


    April 2020
  232. SCHWENDINGER M, Thiry G, De Vos B, Leroux-Roels G, et al
    A Randomized Dose-Escalating Phase I Trial of a Replication-Deficient Lymphocytic Choriomeningitis Virus Vector-Based Vaccine Against Human Cytomegalovirus.
    J Infect Dis. 2020 Apr 21. pii: 5821369. doi: 10.1093.
    PubMed     Abstract available


    March 2020
  233. KURTOVIC L, Atre T, Feng G, Wines BD, et al
    Multi-functional antibodies are induced by the RTS,S malaria vaccine and associated with protection in a phase I/IIa trial.
    J Infect Dis. 2020 Mar 31. pii: 5814271. doi: 10.1093.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Vaccines is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: